Introduction
The treatment outcomes of extranodal NK/T-cell lymphoma have not been satisfactory, 1, 2 even in the cases with localized disease. 3 The prior therapeutic approach with radiotherapy alone for localized disease showed frequent systemic failure, 4, 5 which has led to searching for efficient combination modality treatment with chemotherapy and radiotherapy. However, the efficacy of combined modalities of chemotherapy and radiotherapy has been disappointing. 6 Furthermore, it has been suggested by several groups including ours that patients with extra-upper aerodigestive tract (EUNKTL) had poorer prognosis to conventional anthracycline-based chemotherapy. 7, 8 Few reports have demonstrated promising results with highdose chemotherapy and autologous stem cell transplantation (HDC/ASCT) in NK/T-cell lymphoma patients as a salvage treatment. [9] [10] [11] [12] [13] [14] It is inconclusive, however, from these studies, to consider HDC/ASCT as a standard treatment due to small cohort of patients. In addition, a clear indication of HDC/ASCT has not been established in NK/T-cell lymphomas. Recently, we have proposed a new prognostic model, namely NKIPI (NK/T-cell lymphoma International Prognostic Index), from a large retrospective study of 262 patients. The model comprised of B symptom, stage, lactic dehydrogenase (LDH) and regional lymphadenopathies and showed better prognostic capacity than conventional IPI (International Prognostic Index) scores. 15 In an attempt to investigate a role of HDC/ASCT in NK/ T-cell lymphomas according to NKIPI risk groups, we conducted a subgroup analysis of patients who received HDC/ASCT during the treatment course of the disease and studied the treatment outcomes.
Patients and methods
In our previous study, 304 patients diagnosed as NK/T-cell lymphomas were accrued from 10 tertiary hospitals in Korea from 1991 to 2004. 15 Of 304 patients, we included 262 patients in the analysis. We searched for patients who had received HDC/ASCT as post-remission therapy or salvage treatment from the database and identified 16 eligible patients. All of the 16 patients had pathologically confirmed NK/T cell lymphoma with positive immunostaining results for cytoplasmic CD3 and CD56 and Epstein-Barr virus (EBV) in situ hybridization. 16, 17 To investigate a potential role and the indications of HDC/ASCT in treatment of extranodal NK/T-cell lymphoma, a subset analysis comparing HDC/ASCT recipients and non-recipients was performed in regards to relapse-free survival (RFs) duration and overall survival (OS) duration. The conditioning regimens used for ASCT were BEAM (carmustine, etoposide, cytarabine melphalan) in twelve patients, VCT (VP-16, cyclophosphamide, total body irradiation of 9 Gy) in two patients, VCB (VP-16, cyclophosphamide, busulphan) in one patient and BEAC (carmustine, etoposide, cytarabine, cyclophosphamide) in one patient. BEAM regimen consisted of carmustine (300 mg/ m 2 i.v. on day À6), etoposide (200 mg/m 2 twice daily i.v. on days À5 through À2), cytarabine (200 mg/m 2 twice daily i.v. on days À5 through À2) and melphalan (140 mg/m 2 i.v. on day À1). BEAC regimen consisted of carmustine (300 mg/m 2 i.v. on day À7), etoposide (100 mg/m 2 twice daily i.v on days À6 through À3), cytarabine (100 mg/m 2 twice daily i.v. on days À6 through À3) and cyclophosphamide (35 mg/kg once daily i.v. on days À6 through À3). VCT regimen consisted of etoposide (1.8g/m 2 i.v. on day À7), cyclophosphamide (60 mg/kg once daily i.v. on days À6 through À4) and total body irradiation (TBI) in fractionated doses (3 Gy once daily on days À3 through À1). VCB regimen consisted of etoposide (400 mg/m 2 once daily i.v. on days À5 and À4), cyclophosphamide (50 mg/kg once daily i.v. on days À3 and À2) and busulphan (0.8 mg/ kg four times daily i.v. on days À7 through À5). To calculate dose, ideal body weight or actual body weight, whichever was less, was used. Briefly, PBSCs were mobilized during the hematopoietic recovery following the consolidation therapy hastened by i.v. administration of granulocyte colony-stimulating factor (G-CSF; Filgrastim s , Jeil-Kirin) 10 mg/kg per day. Leukapheresis was initiated when WBC exceeded 1.0 Â 10 9 /ml. A minimum of 2 Â 10 6 CD 34 þ cells/kg body weight were collected using a Fenwell CS 3000 þ cell separator. The collected PBSCs were frozen using a controlled-rate freezer (Cryomed s , Thermo Forma, Marietta, OH, USA) and stored in liquid nitrogen at À1961C until use. After completion of the conditioning regimen, cryopreserved stem cells were thawed at 371C in a water bath and infused through a Hickman catheter using a standard blood administration set without a filter. Patients were premedicated with antihistamines and steroids to minimize the effects of dimethylsulfoxidemediated histamine release.
Statistical analysis
To determine the tendency in clinical features between independent two groups, Fisher's exact test for categorical variables, and Student's t-test for continuous variables were performed. OS and RFS were estimated using the KaplanMeier product-limit method. OS was measured from the date of HDC/ASCT to the date of death or the last followup visit. RFS was calculated from the date HDC/ASCT to the date when the disease relapse was recognized or the date of the last follow-up visit. When compared to historical controls for survival difference, OS, RFS and follow-up duration were measured from the date of diagnosis. Survival rates were compared for statistical differences by using log-rank analysis between subgroups according to the following parameters: stage at presentation, disease status at time of HDC/ASCT, anatomic subtypes of NK/T-cell lymphomas (UNKTL vs EUNKTL) and NKIPI risk groups (Groups 1, 2 vs Groups 3, 4).
Results

Patient characteristics
The characteristics of 16 patients who received HDC/ ASCT are provided in Table 1 . There were 10 male patients and a median age was 36 years (range, 17-54 years). At diagnosis, half of total patients had advanced stage (Ann Arbor stage III-IV) and four patients had EUNKTL. Three patients underwent HDC/ASCT in CR1, six patients in CR2 and seven patients in PR/NR. There were no significant differences in clinical features (sex, age, PS, IPI, stage and LDH) between CR1/CR2 and PR/NR (Table 2) . Comparing the clinical characteristics of CRs with those of non-transplanted historical control group, there was no significant difference except age distribution (median age 34 vs 49, ASCT at CR vs non-ASCT at CR group, P ¼ 0.001) ( Table 3) .
Outcomes
The treatment outcomes are summarized in Figure 1 . Nine patients including CR1 and CR2 received HDC/ASCT as post-remission consolidation treatment, while seven patients (PR/NR) received HDC/ASCT as salvage treatment. Twelve out of 16 patients achieved or maintained CR after HDC/ASCT. Among the twelve patients who achieved CR, five patients have relapsed. One patient (case 10) died of unknown cause after 8 months after transplantation. Five relapsed patients and one patient with persistent disease received salvage treatment. Two patients (case 2 and 6) underwent allogeneic stem cell transplantation (SCT) from unrelated donors and all were alive in remission at last follow-up. The intensity of conditioning was myeloablative. One patient (case 6) attained disease-free survival for more than 4 years. No complete remission was achieved in the other patients who underwent conventional chemotherapy or radiotherapy as salvage treatment (Figure 1 ).
Survival analysis
After a median follow-up duration of 22.4 months, estimated 2-year OS and RFS rates were 71.3712.4% and 25.8714.3%, respectively (Figure 2 ). There was a significant difference in survival according to disease status (CR1/CR2 vs PR/NR) at the time of HDC/ASCT (Figure 3 ). The median OS in CR1/CR2 was not reached, while it was 8 months for patients with PR/NR. The median RFS was 23 months in CR1/CR2 group and 1 month in PR/NR group. The Kaplan-Meier survival curve of OS was not statistically different in CR1/CR2 vs PR/NR (P ¼ 0.108). However, statistically significant difference was demonstrated in RFS of CR1/CR2 vs PR/NR (P ¼ 0.012). A 2-year OS was 56.5%73.3 in 246 patients who did not receive HDC/ASCT. There was a trend toward survival advantage for HDC/ASCT group (n ¼ 16) as compared to the historical control group (n ¼ 246), although it was not statistically significant (P ¼ 0.091, Figure 4a ). In subgroup, analysis according to initial stage and the disease status at transplantation, statistically significant survival advantages were shown in subset of patients receiving HDC/ASCT. Patients who underwent HDC/ASCT at CR (P ¼ 0.049) (Figure 4b ) and patients with stage III or IV disease (P ¼ 0.001) (Figure 4d ) had favorable outcome as compared to those of the historical control group. Patients with NKIPI 3, 4 or EUNKTL, who underwent HDC/ASCT had more prolonged survival as compared to historical controls without statistical significance (P ¼ 0.055 and P ¼ 0.056) (Figure 4f and h ).
Discussion
The role of HDC/ASCT for aggressive lymphoma has been established by large prospective studies including the GELA LNH87-2 and GOELAMS trials. 18, 19 However, the vast majority of these studies had diffuse large-cell, while the proportion of T-cell lymphoma was negligible. Studies on HDC/ASCT in NK/T-cell lymphoma have been seldom reported in particular. The successes of HDC/ ASCT for NK/T-cell lymphoma were reported by Park et al. and Bang et al. 10, 20 Our study which was one of the largest series, demonstrated a trend towards better OS compared with historical controls without statistical significance. 13 Therefore, to clarify the role and the indication for HDC/ASCT in extranodal NK/T-cell lymphoma, we conducted a retrospective study. In this study, we were able to identify several points in regards to potential indications of HDC/ASCT in NK/T-cell lymphoma patients. First, there was a trend towards prolonged survival for HDC/ASCT compared with historical controls despite no statistical significance. In subgroup analysis, HDC/ASCT seemed to be beneficial for patients with CR compared to those with PR/NR at the time of transplantation, which suggests that HDC/ASCT might be feasible as consolidation therapy. Secondly, we demonstrated that HDC/ASCT was more efficient in advanced diseases (Ann Arbor stage III/IV or EUNKTL) or high-risk groups according to NKIPI (Groups 3 or 4), while equivocal outcomes were noticed in localized diseases (stage I/II or UNKTL) or low-risk group were documented through the comparison with historical controls. We, thus, speculate that the strategy of HDC/ASCT may be efficient in treating patients with advanced disease or with NKIPI scores of 3-4. However, a randomized trial is needed to prove definite survival benefit in this subgroup of patients.
Notably, patients who received allogeneic stem cell transplantation as salvage treatment seemed to have prolonged survival, although it is difficult to draw any conclusions from two patients in our series. However, there are several reports of successful treatment of NK/T-cell lymphomas with allogeneic stem cell transplantation, 21, 22 which suggested a possible role of allogeneic stem cell transplantation in NK/T-cell lymphoma patients, especially those who are refractory to induction therapy. Recently, Suzuki et al. has reported the treatment outcome of 40 patients with natural killer-cell lineage neoplasms in Japan. Of the 40 patients, there were 22 patients with extranodal NK/T-cell lymphoma in their series. In retrospective analysis, they demonstrated a prolonged survival in patients who received HSCT as compared to those who did not undergo HSCT with statistical significance. 23 We have conducted a retrospective analysis in a series of NK/T-cell lymphomas to demonstrate the treatment outcome following HDC/ASCT. Although the role of HDC/ ASCT cannot be established through our study due to small sample size and limited statistical power, our study has demonstrated a tendency of favorable survival in NK/ T-cell lymphoma patients with CR at the time of transplantation, advanced disease or high NKIPI scores. Prospective, multi-center study is warranted to assess the efficacy and feasibility of HDC/ASCT in patients with this rare disease. 
